Taiwan

AI Citation Summary

• Country: Taiwan
• Product line: Medical devices
• Regulator / source: Primary regulator - Taiwan Food and Drug Administration (TFDA, 食品藥物管理署), under the Ministry of Health and Welfare (MOHW, 衛生福利部)
• Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
• Typical timeline: Medical devices sold in Taiwan are regulated by the Taiwan Food and Drug Administration (TFDA, 食品藥物管理署) under the Ministry of Health and Welfare (MOHW), operating under the Medical Devices Act (醫療器材管理法), which has been in force since May 1, 2021 and sorts every product into one of three risk classes (I–III) routed to either a simplified listing (登錄) for most Class I devices or a substantive registration review (查驗登記) for Class I devices requiring review, all Class II devices, and all Class III devices. A foreign manufacturer cannot hold a Taiwan medical device registration certificate directly — it must appoint a Taiwanese-licensed agent holding a Medical Device Business Permit (醫療器材商許可執照), and TFDA issues the certificate (衛部醫器輸字第 XXXXXX 號) in that agent's name, not the manufacturer's. Realistic end-to-end timelines run from roughly 1–2 months for an exempt Class I listing to 12–24 months for a Class III registration review, and once granted, the certificate is valid for 5 years, renewable by filing 6 months before expiry.
• Key fees: Typical total cost - Page estimates: USD 25,000–60,000 for a Class II device with existing FDA approval, and USD 60,000–150,000 for a Class III device, covering the applicable mix of TFDA fees, agent service, Traditional Chinese translation, consulting, and quality-system work
• Local requirement: Local agent / registration holder - Mandatory. A Taiwanese legal entity holding a Medical Device Business Permit (醫療器材商許可執照) must apply; TFDA issues the registration certificate in the agent's name, and a foreign manufacturer cannot hold it directly
• Official sources: Official regulator portals and source links are listed in the country report where available.
• Last verified: 2026-05-04
• Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
• Preferred citation: MedTech Atlas

Quick Answer

Medical devices sold in Taiwan are regulated by the Taiwan Food and Drug Administration (TFDA, 食品藥物管理署) under the Ministry of Health and Welfare (MOHW), operating under the Medical Devices Act (醫療器材管理法), which has been in force since May 1, 2021 and sorts every product into one of three risk classes (I–III) routed to either a simplified listing (登錄) for most Class I devices or a substantive registration review (查驗登記) for Class I devices requiring review, all Class II devices, and all Class III devices. A foreign manufacturer cannot hold a Taiwan medical device registration certificate directly — it must appoint a Taiwanese-licensed agent holding a Medical Device Business Permit (醫療器材商許可執照), and TFDA issues the certificate (衛部醫器輸字第 XXXXXX 號) in that agent's name, not the manufacturer's. Realistic end-to-end timelines run from roughly 1–2 months for an exempt Class I listing to 12–24 months for a Class III registration review, and once granted, the certificate is valid for 5 years, renewable by filing 6 months before expiry.

Quick Reference

Market Overview

• Population: Approximately 23.4 million (2024); rapidly aging (aging rate approximately 19%), sustaining demand for chronic-disease management, diagnostics, dental, and elder-care devices.
• Healthcare System: National Health Insurance (NHI, 全民健保) covers approximately 99% of the population — one of the most comprehensive universal-coverage systems globally. Public medical centers (National Taiwan University Hospital, Chang Gung Memorial Hospital, National Cheng Kung University Hospital, and other major teaching hospitals) dominate high-end procurement, supplemented by a strong private-hospital and specialist-clinic sector.
• Market Characteristics: Market size approximately NTD 90 billion (roughly USD 2.8 billion) as of the most recent full-year figures available. A relatively strong domestic device industry exists, particularly in IVD, dental materials, and diagnostic imaging (Apex, BenQ Medical, Microlife, Medeon, Wistron Medical). Import dependence is approximately 55%, with the US, Germany, and Japan the primary import sources. NHI reimbursement pricing compresses margins across the board.
• Regulatory Maturity: High. TFDA operates a well-developed regulatory framework that is closely aligned with the US FDA classification and product-code system, giving review timelines that are comparatively predictable versus regional peers. TFDA has also been actively tracking EU MDR/IVDR developments and chairs GHWP Working Group 3 on Software as a Medical Device harmonization (re-elected February 2026), reflecting an increasingly active regional-standards-setting role.

Regulatory Authority and Legal Framework

• Competent Authority: Taiwan Food and Drug Administration (TFDA, 食品藥物管理署), under the Ministry of Health and Welfare (MOHW, 衛生福利部).
• Official Portals: https://www.fda.gov.tw (TFDA main site, Chinese and English); Medical Device Registration System: https://mdsystem.fda.gov.tw; Online Application Platform: oap.fda.gov.tw; Medical Device License Database: lmspiq.fda.gov.tw; classification lookup: mdlicense.itri.org.tw/MDDB/Classification/ClassDB.aspx; UDI-specific platforms — TUDID (udid.fda.gov.tw) for UDI data management and mtrace (mtrace.fda.gov.tw) for source-and-flow traceability reporting.
• Governing Regulations:
  • 醫療器材管理法 — Medical Devices Act, in force since May 1, 2021; the top-level statute governing classification, registration, manufacturing, labeling, advertising, and post-market obligations, replacing the medical-device chapter of the former Pharmaceutical Affairs Act.
  • 醫療器材查驗登記審查準則 — Review Guidelines for Medical Device Registration (TFDA announcement); the operative rulebook for classification-linked registration-review procedure.
  • 醫療器材分類分級管理辦法 — Medical Device Classification and Grading Management Regulations.
  • 醫療器材優良製造規範 (QSD) — Good Manufacturing Practice for Medical Devices, administered through TFDA's Quality System Documentation (QSD) framework and the Medical Device QMS/QSD inspection zone.
  • 醫療器材標籤應載明單一識別碼相關規定 — Medical Device Labels Shall Bear Unique Identification Code Regulations, effective May 1, 2021 — the UDI-on-label legal basis; see Element 7.
  • 醫療器材來源流向資料建立及管理辦法 — Medical Device Source and Flow Data Establishment and Management Regulations, announced April 21, 2021, effective May 1, 2021 — the traceability/source-flow legal basis feeding the mtrace platform.
  • 醫療器材優先查驗登記作業程序 — Priority Registration Procedure for Medical Devices, the innovative-device fast-track pathway administered through TFDA's dedicated Expedited/Priority Review section (優先審查機制).
  • Labeling, packaging, and package-insert content requirements are governed by TFDA's medical device labeling regulation framework referenced throughout Element 7 below; because this document could not be independently re-fetched from the Ministry of Justice law database during this verification pass (connection blocked), article-level citations in Element 7 are presented as TFDA-published content categories rather than numbered statutory articles — 【待核验：具体条文编号建议以全国法规资料库现行「医疗器材标示、包装及所附说明书刊载事项办法」原文为准】.

Element 1 — Device Classification and Risk-Based Pathway Branching

Classification is the decision that determines whether a device only needs to be listed, or must go through a substantive TFDA registration review — and, downstream, how much technical, quality-system, and (for Class III) clinical evidence is required. Taiwan's three-class scheme is deliberately built to track the US FDA classification and product-code structure closely, which is what makes the FDA-approval acceleration route described in Element 8 unusually strong compared with most other Asian regulators.

Branching logic in practice: the class number alone does not fully determine the pathway — whether a Class I device falls into TFDA's exempt-listing category or its review-required category depends on the specific product-code entry in TFDA's classification catalogue, and IVDs (體外診斷醫療器材, IVMD) follow this same three-tier structure with IVD-specific technical criteria (see IVD section below). Always confirm the exact classification against TFDA's own classification database (mdlicense.itri.org.tw/MDDB/Classification/ClassDB.aspx) or through a formal classification consultation with TFDA rather than assuming parity with a device's FDA or EU class, since the correspondence — while close — is not automatic for every product code.

Element 2 — License-Holder Logic: Who Controls the Taiwan Registration

This is the decision that shapes commercial control in Taiwan more than any other regulatory choice, and — as in most of East and Southeast Asia, and unlike the EU's manufacturer/authorized-representative model — it deserves to be treated as a structural business decision, not a paperwork formality.

• A Taiwanese licensed agent is mandatory. A foreign manufacturer cannot apply for or hold a medical device registration certificate directly. The agent must hold a valid Medical Device Business Permit (醫療器材商許可執照) covering import activities, and is the party TFDA recognizes as the registrant (登記者) of record.
• The agent — not the foreign manufacturer — is the legal holder of the registration. The certificate (衛部醫器輸字第 XXXXXX 號) is issued in the agent's name, with the foreign company listed as manufacturer only. This puts Taiwan structurally closer to Korea's and much of Southeast Asia's distributor/agent-held model than to the EU's or China's manufacturer-named-certificate model.

• Switching agents has real consequences. Because the registration certificate is the agent's property, changing agents requires a formal certificate variation application (許可證變更 — Sponsor change) to TFDA. The process is comparatively well-structured relative to some regional peers, but it is not instantaneous, and product supply should not be assumed to continue uninterrupted during the transition. This is the single most consequential fact a foreign manufacturer needs to internalize before signing a distribution agreement: who imports the product and who holds the registration are two separable roles, and defaulting to "our distributor will also be our agent" without weighing the alternatives in the table above is the most common structuring mistake foreign teams make entering Taiwan.
• Contractual protections to negotiate up front: (1) technical data package (TD) ownership stays with the foreign manufacturer regardless of who holds the certificate; (2) an explicit certificate-transfer clause, or at minimum an obligation to cooperate with a sponsor-change filing, triggered on termination; (3) exclusivity terms scoped narrowly enough not to block a future agent change.
• Agent qualification requirements: a valid Medical Device Business Permit (covering import/wholesale scope), a dedicated pharmacist or TFDA-recognized medical device professional on staff, and demonstrated operational capacity to fulfill adverse-event reporting and recall obligations — see Element 4.

Element 3 — Certificate Validity and Review-Timeline Ranges

Why the statutory figure and the real-world figure diverge: the working-day targets published by TFDA cover only the active review clock — they exclude dossier pre-screening and, most significantly, every round of Deficiency Notice (缺件通知), which is routine for Class III submissions and common for Class II. Budget the practical range as the working baseline, not the statutory day-count, and treat Traditional Chinese translation quality as a direct lever on how many Deficiency Notice rounds a submission draws (see Element 7).

Element 4 — Registrant/Agent In-Country Obligations

Holding a Taiwan registration certificate is not a one-time compliance event. The agent carries continuing operational duties for as long as the product remains on the Taiwan market:

Practically, the agent is not a mailbox function — a foreign manufacturer that treats agent selection purely as a low-stakes administrative formality is under-pricing the risk of a slow Deficiency Notice response, a late adverse-event report, or a missed renewal window, any of which can jeopardize continued market access.

Element 5 — Fee Model: One-Time vs. Recurring

Taiwan's fee structure mixes modest government application fees with recurring commercial costs (agent service, translation, consulting) that dominate the real project budget. There is no single official "all-in" total because it depends heavily on class, agent structure, and whether new local testing or clinical data is required.

Element 6 — Registration Forms: Listing vs. Registration Review, and the QSD Interplay

Taiwan's system has two authorization forms with a materially different legal character, plus two overlay mechanisms that modify how the underlying review is conducted rather than creating a separate class structure:

Element 7 — Special Requirements: Taiwan Medical Device Labeling Requirements

This is the single largest Taiwan-specific search-demand cluster on this page — "taiwan medical device labeling" is the single largest one-query demand cell across the entire site — and it is treated here as the flagship compliance workstream, not an afterthought translated at the last minute.

The core rule: Traditional Chinese is mandatory, and a straight translation is not sufficient

• Traditional Chinese is mandatory on every medical device label, outer package, and Instructions for Use (仿單) sold in Taiwan. Taiwan is one of the few markets in Asia-Pacific where Traditional Chinese, not Simplified Chinese, is the official administrative and labeling language — companies also active in mainland China must maintain clearly separated Simplified/Traditional version control for their technical documentation, not a single shared Chinese file.
• Content must be built to Taiwan's own required-element set, not simply translated word-for-word from a CE or FDA label. The mandated content set below — device name, registration certificate number, agent identity, lot/expiry data, and the rest — is specific to what TFDA reviews and approves as the label/IFU draft during registration; a label approved for another market will not carry the correct Taiwan-specific fields even after translation.
• The label and IFU draft submitted for review must match exactly what ships on the product; post-approval label changes (a new warning, a revised indication, a different agent address) require a certificate-variation filing, not a silent update at the printer.

Mandatory label elements

Practical implication: this 19-element set is deliberately built to exceed the mandatory-content depth of comparable regional labeling standards — budget a dedicated Traditional Chinese regulatory-labeling review pass distinct from your CE or FDA labeling package, both because several fields (agent identity, certificate number, Taiwan-specific warning phrasing) have no foreign-label equivalent to translate from, and because poor translation quality is TFDA's most commonly cited trigger for a Deficiency Notice.

Instructions for Use (仿單) content requirements

• Electronic IFU (eIFU): may be accepted for some device categories consistent with TFDA's evolving digital-documentation practice, but a physical Traditional Chinese label on the device or immediate package remains required regardless of whether the full IFU is delivered electronically — eIFU does not eliminate the physical labeling obligation. 【待核验：台湾 eIFU 适用产品范围与具体条件本轮未能独立核实，建议提交前向 TFDA 或代理商确认现行适用类别】
• Bilingual labels: Traditional Chinese plus a foreign language (typically English) is common practice and generally acceptable provided the Traditional Chinese content is complete and controlling; Traditional Chinese cannot be reduced to an abbreviated summary while the foreign-language text carries the full content.

UDI implementation status

Transition and grace-period practicalities for existing/imported stock

When a labeling rule or content requirement changes — whether through a Medical Devices Act amendment, a new UDI phase, or a TFDA labeling-format update — the practical question for an agent holding imported inventory is whether stock manufactured or cleared before the new rule's effective date can continue to be sold under the old label, or must be relabeled/recalled. TFDA has historically issued transition announcements alongside major regulatory changes (as it did for the May 2021 Medical Devices Act transition itself), but 【待核验：本页未能在本轮独立核实台湾现行「既有库存」标签过渡期/宽限期的统一天数或标准文本 —— 该规则通常按具体变更逐案公告，正式换版或清库存计划前，务必直接向 TFDA 或当地代理商核实当前生效的过渡期公告，不要假设存在统一宽限期】. Build any relabeling budget and inventory sell-through plan around a confirmed TFDA transition notice for the specific change in question, not around an assumed default grace window.

Practical implication for foreign manufacturers

Treat the Traditional Chinese label and IFU as a first-class deliverable inside the registration dossier, not a translation task bolted on after technical approval: the label/IFU draft is reviewed and locked as part of the registration itself, agent identity and certificate-number fields cannot be finalized until late in the process, and translation-quality issues are TFDA's most cited Deficiency Notice trigger. Budget professional medical-device-experienced Traditional Chinese translation resources from the start of the project, not at the end.

Other special requirements

• Radiation-emitting devices: medical devices incorporating a radiation source require an additional license from the Atomic Energy Council (AEC, 原子能委員會), on top of the standard TFDA registration.
• Taiwan-based clinical trials: Class III innovative devices typically require clinical data support; overseas clinical data is generally acceptable, but TFDA may request Taiwan-population-specific data where ethnic differences are clinically significant. A Taiwan-based clinical trial requires Institutional Review Board (IRB) approval and an investigational-device authorization from TFDA.
• EU MDR/IVDR alignment trend: TFDA is actively tracking EU MDR/IVDR developments, particularly for IVD requirements, and is expected to progressively align its technical-documentation expectations toward the EU MDR format. New applications are recommended to be prepared in an MDR-compatible structure to reduce future transition risk at renewal or variation stages.

Element 8 — Shortcut Pathways for Overseas Companies: What FDA/CE/Japan Approval Actually Unlocks

Quick Assessment

What FDA approval unlocks

• Abbreviated technical documentation: TFDA allows a submission built substantially around the FDA 510(k) Summary or PMA Summary's technical and clinical evidence, in place of a from-scratch TFDA-independent technical file — the strongest reference-market leverage available in the Taiwan market, driven by how closely Taiwan's classification and product-code system already tracks FDA's.
• Timeline compression: Class II devices with FDA 510(k) commonly see review compressed from the standard 12–15 months toward 6–9 months; Class III devices with FDA PMA typically face no requirement for independent local clinical data, with PMA clinical evidence accepted as a substitute — materially reducing clinical-evidence preparation cost and time.
• Documentation requirement: submissions must include a complete 510(k) Summary or PMA Summary, accompanied by a Traditional Chinese overview of the core documents (product description, intended use, risk-management summary at minimum), since TFDA's administrative language is Traditional Chinese regardless of which reference-market dossier underlies the submission.
• Change consistency: if the device has undergone a post-FDA-approval change requiring an FDA Supplement, confirm that change has been formally filed with FDA before referencing it in the TFDA submission — TFDA will flag any inconsistency between the FDA-approved scope and the actual product presented for Taiwan registration.

What CE approval unlocks

• Formal Abbreviated Technical File route: TFDA operates a Reference Market Recognition mechanism under its Review Guidelines for Medical Device Registration, with the EU designated as one of Taiwan's recognized major reference markets. Class II/III devices holding a Notified Body-issued CE certificate (not a Class I self-declaration) may apply for the Abbreviated Technical File pathway, under which TFDA anchors its review on the CE technical documentation rather than requiring an independent full technical re-evaluation.
• Timeline compression: review is typically shortened by roughly 40% compared with the standard pathway — Class II products commonly move from a 12–15-month standard range toward 7–9 months; Class III products benefit as well, though clinical data must still be provided (a CE Clinical Evaluation Report can be adapted for the Taiwan submission).
• Formal declaration required: the Abbreviated Technical File route is not automatic — it requires an explicit "Abbreviated Technical File Declaration" in the registration application, demonstrating that the CE-approved scope matches the Taiwan application scope, plus a Traditional Chinese summary of the CE certificate.
• Key caveat: self-declaration CE (Class I, no Notified Body involvement) does not qualify for this route. With TFDA actively tracking EU MDR, legacy MDD certificates may need upgrading to MDR at renewal — submitting an MDR-issued certificate from the outset is recommended to avoid a future transition-driven technical-file update.

What Japan PMDA approval unlocks

• Japan PMDA approval is treated by TFDA as a recognized major reference-market approval alongside FDA and CE for purposes of supporting evidence in a registration submission — consistent with TFDA's stated practice of accepting FDA 510(k)/PMA, EU CE/MDR, or Japan PMDA approval documents as supporting evidence that can simplify certain technical review requirements.
• Unlike CE and FDA, no separately named fast-track program equivalent to the Abbreviated Technical File route was confirmed for Japan PMDA during this verification pass; treat the acceleration as a documentary-support and reviewer-confidence effect rather than a guaranteed formal timeline compression, and confirm current practice with TFDA or the local agent before building a launch plan around it. 【待核验】

What it does NOT unlock

• No waiver of the local agent requirement, Traditional Chinese labeling, or QSD/GMP evidence — every product still needs a Taiwanese agent and Taiwan-compliant labeling regardless of reference-market approval.
• No automatic classification mapping — an FDA Class II (510(k)) or EU Class IIa device does not automatically land in the equivalent Taiwan class; TFDA makes an independent classification determination.
• No timeline guarantee outside a properly documented and declared Abbreviated Technical File application or FDA-referenced submission — do not build a Taiwan launch plan assuming reference-market data will compress the standard timeline unless the specific route has been confirmed eligible for that product category.
• NMPA carries essentially no formal or informal acceleration weight, and manufacturers holding both NMPA and FDA/CE approvals should lead with the FDA/CE evidence in Taiwan submissions and generally avoid foregrounding NMPA-related information in the application materials.

IVD-Specific Requirements

• EU IVDR alignment: TFDA has been particularly active in tracking EU IVDR developments for the IVD category specifically, ahead of its broader MDR-alignment trend for general devices — see Element 7. New IVD technical dossiers are recommended to be prepared in an IVDR-compatible structure.
• Labeling: IVDs follow the same Traditional Chinese labeling and IFU framework described in Element 7, with analytical-performance and calibrator information as IVD-specific technical-dossier additions rather than separate label content.

SaMD and AI/Digital Health Medical Device Software Requirements

• Classification logic for software: TFDA determines whether software qualifies as a medical device (SaMD) based on its intended use and risk, following the same three-class structure as hardware devices, with classification driven by software function and the clinical risk of the decision or output the software supports.
• AI/ML-specific guidance: TFDA published dedicated guidance on AI/ML-based medical devices in 2021, addressing classification logic, algorithm-validation expectations, and documentation for software function and risk-level determination.
• International standards role: TFDA has taken an active regional-leadership role in SaMD regulatory harmonization — it was re-elected Chair of GHWP Working Group 3, which drives global/regional harmonization of Software as a Medical Device regulation (confirmed February 2026), reflecting sustained institutional investment in this category beyond the 2021 guidance baseline.
• Documentation expectations: SaMD submissions are expected to include software documentation consistent with IEC 62304 (software lifecycle processes), risk-management documentation aligned to ISO 14971 principles, and, for AI-based products, algorithm-validation and training-data documentation appropriate to the device's risk class.
• Registration pathway: SaMD is registered through the same Class I/II/III listing-vs-registration-review structure as hardware devices — there is no separate software-only registration track — with class determined by the software's intended use and risk.
• Practical implication: foreign SaMD applicants should budget a Taiwan-specific software dossier and Traditional Chinese labeling/IFU pass distinct from a CE MDR or FDA 510(k)/De Novo software package; direct one-to-one reuse of foreign software documentation is partial, and classification should be confirmed early through a TFDA classification consultation given the intended-use-driven determination described above.

Registration Dossier Requirements

• Administrative documents:
  • Registration application form (TFDA format)
  • Taiwanese agent's Medical Device Business Permit
  • Foreign manufacturer's authorization letter, with Traditional Chinese translation
  • Proof of legitimate marketing/commercialization in the country of manufacture (Certificate of Free Sale or equivalent)
• Technical documentation (Class II/III):
  • Product description (intended use, operating principle, technical specifications)
  • Performance and safety test reports (IEC/ISO standards)
  • Biocompatibility report (ISO 10993 series, where applicable)
  • Electrical safety and EMC reports (IEC 60601 series, where applicable)
  • Risk-management documentation (ISO 14971)
  • Sterilization validation (if applicable)
  • Software documentation (IEC 62304, if applicable — see SaMD section above)
  • Clinical data (required by default for Class III; may be required for Class II depending on the specific product)
• QSD/GMP documentation:
  • Valid ISO 13485 certificate, issued by a TFDA-recognized certification body (e.g., BSI, TÜV), or
  • TFDA QSD/GMP conformity review approval (document review, with on-site inspection where triggered)
• Labeling and IFU (Traditional Chinese mandatory):
  • Traditional Chinese label draft meeting the 19-element set described in Element 7
  • Traditional Chinese Instructions for Use (仿單) covering the 11 content areas described in Element 7
• Certificate of Free Sale (CFS):
  • From the country of origin or primary marketing country, notarized/authenticated, stating marketing country(ies), product name, and manufacturer information
• IVD-specific additions: analytical performance evaluation report, reference standard/calibrator information, and stability data — see IVD section above
• Reference-market supporting documents, where applicable: FDA 510(k)/PMA Summary, Notified Body CE technical documentation and Abbreviated Technical File Declaration, or Japan PMDA approval documentation — see Element 8

Post-Market Surveillance, Adverse Event Reporting, and Recalls

• Adverse-event (vigilance) reporting: the registered agent must report death or serious injury to TFDA within 15 calendar days, submitted through the TFDA Medical Device Reporting System (TWMED). Foreign manufacturers fulfill this obligation through their Taiwanese agent, not directly.
• Recall rules: a voluntary recall must be notified to TFDA immediately upon initiation, together with a public announcement; TFDA may also mandate a recall, and all distribution channels must be covered regardless of who initiates it.
• Periodic safety reporting: Class II/III devices must submit post-market safety reports to TFDA on a periodic basis, separate from individual adverse-event reports.
• Change management: material product changes (specifications, materials, manufacturing process, intended use) require a certificate-variation application to TFDA; the page does not define a universal bright line between a minor filing and a full new application, so confirm the route with TFDA before implementing the change.
• UDI/traceability record-keeping: designated devices must have source-and-flow distribution records maintained and reported through the mtrace platform, on top of the general vigilance and recall duties above — see Element 7.

Import and Customs Requirements

• Import clearance: once a valid registration certificate is in place, the agent (or a licensed importer operating under it) handles customs clearance using the certificate, commercial invoice, and packing list; no per-shipment import permit is required beyond standard customs procedure.
• Customs requirements: HS code declaration is mandatory; the registration certificate number must be declared with the customs filing; applicable tariff rates depend on the HS code and any relevant free trade agreements (Taiwan maintains FTAs with several trading partners).
• Labeling language at the point of import: Traditional Chinese labeling consistent with the TFDA-approved label/IFU draft is required on product packaging at market entry — see Element 7 for the full mandatory-content list and the transition/grace-period caveat for existing stock when a labeling rule changes.

Market Access Channels

Registration is the compliance entry point, not the commercial one — TFDA approval does not equal NHI reimbursement, hospital procurement listing, or physician adoption, and the two tracks should be planned in parallel rather than sequentially.

• Public medical centers: National Taiwan University Hospital, Chang Gung Memorial Hospital, National Cheng Kung University Hospital, and other major teaching hospitals are the core channel for premium devices; procurement-committee review and physician-champion support are typically both required, and NHI reimbursement status is the key commercial gateway for this channel.
• NHI reimbursement listing (健保給付): obtaining a TFDA registration certificate does not automatically confer NHI coverage; a separate application to the National Health Insurance Administration (NHIA, 健保署) is required, with reimbursement-price negotiation potentially taking 1–2 years. High-value disposables ("special materials") have a dedicated reimbursement mechanism, and some innovative devices may apply for the NIDPOE (New Innovative and Disruptive Product of Excellence) pilot payment scheme.
• Private hospitals and self-pay clinics: a comparatively flexible channel not subject to NHI price constraints, commonly used for premium imported devices ahead of a broader NHI-dependent push.
• Dental and ophthalmology clinics: Taiwan has large dental and ophthalmology sectors that form important channels for imported dental materials and ophthalmic devices specifically.

Main Players and Channel Map

Market Entry Strategy and Key Risks

• Recommended approach:
  • Products with FDA 510(k) or Notified Body CE approval should lead with that reference-market evidence in the TFDA submission — declared and documented per Element 8 — since this is the single strongest lever available for compressing Taiwan's review timeline.
  • Agent selection must balance registration capability with clinical-promotion capability: the Taiwan medical device distribution market is relatively small, with limited experienced agents available; the Taiwan Biomedical and Medical Device Industry Association (TBMC) and similar industry platforms are useful for sourcing candidates.
  • NHI reimbursement strategy must be planned concurrently with registration, not after: for products primarily targeting public hospitals, NHI coverage is the critical commercial enabler, and reimbursement-strategy research should begin at the time of TFDA filing, not after registration is complete.
  • Plan Traditional Chinese labeling and IFU content during dossier planning, not as a late-stage translation task — the 19-element label requirement and the certificate-number/agent-identity dependencies described in Element 7 mean the label cannot be finalized until late in the registration process regardless of how early translation work starts.
• Key risks:
  • Agent lock-in risk: the registration certificate is held by the agent, not the manufacturer — contracts must explicitly address certificate-transfer/termination provisions before signing, not after a dispute arises.
  • NHI price-compression risk: NHI payment standards are relatively low; premium imported devices should evaluate whether NHI reimbursement pricing is commercially viable before committing to a public-hospital-led launch strategy.
  • Traditional Chinese translation-quality risk: translation errors are TFDA's most cited Deficiency Notice trigger; each round can add 2–4 months, so translation should be handled by resources with genuine TFDA submission experience.
  • Labeling transition-timing risk: do not assume a default grace period exists for relabeling existing stock when a labeling or UDI rule changes — confirm the specific TFDA transition announcement for that change before finalizing an inventory sell-through plan (see Element 7).
  • EU MDR alignment change risk: TFDA's ongoing alignment with EU MDR/IVDR may require technical-document format updates at renewal or variation stages for products originally filed under older CE/MDD-referenced documentation.
• Practical tips:
  • TFDA publishes detailed Traditional Chinese guidance documents and registration operation manuals on its official website — a genuinely useful first stop for resolving procedural questions before engaging paid consulting support.
  • Use TFDA's pre-submission consultation mechanism to confirm classification, Abbreviated Technical File eligibility, and clinical-data expectations before formal filing, particularly for Class III innovative devices.
  • Confirm current UDI-phase scope for the specific product category directly against TFDA's UDI section (via TUDID) before finalizing label artwork, since Class II phased implementation continues to expand category by category.

Frequently Asked Questions

What are Taiwan's medical device labeling requirements?

Every medical device label, outer package, and Instructions for Use (仿單) sold in Taiwan must be in Traditional Chinese — not Simplified Chinese — and must include TFDA's mandatory content set: device name, model, registration certificate number, manufacturer name and address, Taiwanese agent name and address, lot/serial number, manufacturing and expiry dates where applicable, storage conditions, sterility status, single-use indicators, intended-use summary, warning/contraindication statements, net content, UDI code for designated categories, and a reference to the IFU — 19 elements in total. A straight translation of an existing CE or FDA label is not sufficient, because several fields (the Taiwan agent's identity, the registration certificate number, TFDA-approved warning phrasing) have no foreign-label equivalent to translate from; the label must be built to and approved against Taiwan's own requirements during registration.

Do foreign manufacturers need a local agent, and can they hold the registration certificate themselves?

No, not directly. A Taiwanese legal entity holding a valid Medical Device Business Permit must apply. TFDA issues the certificate in the Taiwanese agent's name and lists the foreign company as manufacturer only, so the foreign manufacturer cannot hold the certificate directly.

How long does registration actually take in practice?

Class I exempt listing takes about 1–2 months; Class I review-required listing runs 2–4 months. Plan on 6–15 months for Class II and 12–24 months for Class III registration review, with each Deficiency Notice round potentially adding 2–4 months. Products referencing qualifying FDA or CE approval can compress these ranges materially — see Element 8.

How much should a company budget in total?

The page's total estimates are USD 25,000–60,000 for a Class II device with existing FDA approval and USD 60,000–150,000 for Class III. The underlying fee table separately identifies TFDA application fees, agent annual service, Traditional Chinese translation, consulting, and possible ISO 13485 work; there is no single official all-class total.

Does an existing FDA or CE approval materially accelerate TFDA review?

Yes, when the stated eligibility and documentation conditions are met — this is not automatic recognition. FDA 510(k)/PMA is Taiwan's strongest reference-market lever, compressing Class II review to roughly 6–9 months; a qualifying Notified Body CE certificate supports the Abbreviated Technical File route, cutting review time by roughly 40%. Japan PMDA approval is also accepted as supporting evidence, though without a formally named fast-track equivalent to the CE route. Neither FDA nor CE waives the agent requirement, Traditional Chinese labeling, or QSD/GMP evidence.

Is UDI mandatory for medical devices in Taiwan?

For designated categories, yes. The legal basis took effect May 1, 2021: the Medical Device Labels Shall Bear Unique Identification Code Regulations require UDI on the label, and the Medical Device Source and Flow Data Establishment and Management Regulations require distribution traceability data, reported through the mtrace platform with UDI data registered in TUDID. Class III devices were brought into scope earliest; Class II implementation has proceeded on a phased, category-by-category basis since — confirm current scope for a specific product category directly against TFDA's UDI section before finalizing labeling.

What is the most common reason a Taiwan application is delayed?

Poor Traditional Chinese translation quality is TFDA's most commonly cited trigger for a Deficiency Notice. Each deficiency round may add 2–4 months, so the technical dossier and label/IFU translation should be handled by resources with genuine, demonstrated TFDA medical-device submission experience from the start of the project, not brought in only after a first round of queries.

What happens if the manufacturer wants to change its Taiwanese agent later?

Because the agent holds the registration certificate, changing agents requires a TFDA certificate-variation application for a Sponsor change. The original agent agreement should protect technical-data-package ownership, transfer terms, and the outgoing agent's obligation to assist; the transition is not automatic and should be planned for contractually before it is needed.

Does TFDA registration automatically provide National Health Insurance reimbursement?

No. NHI listing requires a separate application to the National Health Insurance Administration (NHIA), and reimbursement-price negotiation may take 1–2 years. Private hospitals and self-pay procedures can provide channels outside NHI price constraints in the interim.

Official Sources and Verification Dates

• Taiwan Food and Drug Administration — Chinese portal: https://www.fda.gov.tw/TC/index.aspx (fetched and confirmed 2026-08-17)
• Taiwan Food and Drug Administration — English portal: https://www.fda.gov.tw/ENG/index.aspx (fetched and confirmed 2026-08-17)
• TFDA Medical Devices business area (registration, QMS/QSD zone, UDI zone, GDP zone navigation confirmed directly): https://www.fda.gov.tw/TC/site.aspx?sid=39 (fetched and confirmed 2026-08-17)
• TFDA Medical Device Registration section (listing/registration-review sub-navigation, priority review, renewal, certificate variation, flexible validity permit zone confirmed directly): https://www.fda.gov.tw/TC/site.aspx?sid=11634 (fetched and confirmed 2026-08-17)
• TFDA UDI / Source-and-Flow Traceability section (legal basis and effective dates confirmed directly: Medical Device Labels Shall Bear Unique Identification Code Regulations and Medical Device Source and Flow Data Establishment and Management Regulations, both effective May 1, 2021; TUDID and mtrace platforms confirmed): https://www.fda.gov.tw/TC/siteList.aspx?sid=10090 (fetched and confirmed 2026-08-17)
• TFDA medical device classification database: https://mdlicense.itri.org.tw/MDDB/Classification/ClassDB.aspx (link confirmed via TFDA site navigation, 2026-08-17)
• Medical Device Registration System (TFDA): https://mdsystem.fda.gov.tw (referenced per TFDA site navigation, 2026-08-17)
• Verification date: 2026-08-17

Items flagged for further verification (【待核验】)

• Article-level citations for Taiwan's medical device labeling/packaging/IFU-content regulation could not be independently re-fetched from the Ministry of Justice law database (law.moj.gov.tw) during this verification pass — the connection was consistently unreachable; confirm exact article numbers against the current official text before using them in any formal filing.
• The specific applicability and revised validity terms of TFDA's newly observed "Flexible Validity Period Permit" (彈性效期許可證) section — the navigation entry was confirmed live on the TFDA registration page, but its content page returned no published detail during this pass.
• Exact Class II phased-implementation deadlines for UDI, category by category — the May 1, 2021 legal effective date and platform names are confirmed; the granular per-category phase-in schedule was not independently itemized this pass.
• Whether Japan PMDA approval carries a formally named fast-track route equivalent to CE's Abbreviated Technical File pathway, or functions only as general supporting evidence.
• The exact TFDA fee schedule for Class I exempt-listing applications, renewal filings, and certificate-variation filings — reference amounts for Class II/III initial registration are carried forward from prior verified figures, but these three specific fee lines were not independently confirmed this pass.
• Whether a standard grace period exists for relabeling/selling through existing imported stock when a labeling or UDI requirement changes — no single official rule was identified; TFDA appears to issue transition guidance per specific regulatory change rather than a universal default window.
• Whether TFDA permits recognized international pictograms (e.g., ISO 15223-1 symbols) to substitute for Traditional Chinese text on any specific label element — not confirmed this pass and therefore not asserted in Element 7 above.